Foundation Medicine

Our collaboration with Merus will work towards developing Foundation Medicine’s RNA platform as a companion diagnostic for treatment options in NRG1 fusion-driven tumors. Learn more: https://bit.ly/3yWymOU

Our team is looking forward to joining industry leaders at this year’s 14th Annual World CB & CDx Summit in Boston! Excited to dive into the latest innovations in precision oncology and companion diagnostic development. Learn more & schedule a time with our team at the link here: https://bit.ly/3Mmkfp7

Thank you, summer interns! Our 2024 summer internships wrapped up last week. Throughout the summer, interns provided support across our Commercial, Operations, Tech, Engineering and R&D teams, bringing their dedication, passion and hard work to the office each and every day. Scroll through to hear perspectives on why some of our interns chose to spend their summer at Foundation Medicine. #WeAreFMI

Through our partnership with BioversityMA, we aim to make the life sciences industry inclusive and equitable, ensuring everyone has a chance to contribute to and benefit from advancements in biotechnology. Read more about our involvement, why our VP of Talent Acquisition, Ian Ide, joined the board of Bioversity, and hear the inspiring stories of Christina and Lazaro, two inspiring graduates of the program who brought their passion and talent to our team: https://bit.ly/4g50AIf #WeAreFMI

Are you using liquid biopsy to its potential? Learn from a panel of experts as they share information and perspectives about biomarker testing guidelines and the biomarker ctDNA tumor fraction reported by Foundation Medicine’s liquid biopsy test. Register today for our Foundation Frontiers webinar on advanced prostate cancer at the link here: https://bit.ly/4fHQWL5

A new study published in Clinical Cancer Research shows that Foundation Medicine’s homologous recombination deficiency signature (HRDsig) can offer a new approach to identify patients who may benefit from PARP inhibitors as maintenance therapy (mPARPi), even among patients with no BRCA1/2 alterations. Using real-world, de-identified data, researchers compared the effectiveness of mPARPi in real-world practice by BRCA1/2 alteration status and two genomic scar signatures, HRDsig and genomic loss of heterozygosity (gLOH). Click here to read more about study highlights, results & takeaways at the link here: https://bit.ly/3yli9CP

We strive to foster an environment where diverse perspectives and backgrounds are recognized, appreciated and embraced. Click through to hear from some of our colleagues. Our 2023 Diversity, Equity and Inclusion Annual Report is now available at the link here: https://bit.ly/3yiZasy

Today we recognize World Lung Cancer Day. In our work to transform cancer care, we are committed to spreading awareness and knowledge around lung cancer. We’re proud to support the lung cancer community and organizations such as GO2 for Lung Cancer in all of their efforts in research, education and advocacy. Hear more perspectives and learn about the progress that has been made in lung cancer diagnosis, treatment and outcomes at the link here: https://bit.ly/3A4O0YV

New Publication – Proud to share that recent #research published in The Lancet showcased positive results of CUPISCO, a randomized, precision oncology study designed to prospectively assess the efficacy of molecularly guided therapy in patients w/ unfavorable subsets of cancer-of-unknown-primary. Click the link here to read the full publication and to learn more: https://bit.ly/3yoGFml

Our passion to advance cancer care stems from the individuals that make up our team. We’re proud to highlight two of our dedicated account executives, Megan and Ethan, who are celebrating significant milestones — Megan’s 20 years cancer-free and Ethan’s 10 years cancer-free. Join us in honoring these remarkable individuals whose resilience and dedication inspire us all: https://bit.ly/3yu4rNL #WeAreFMI